Search
Non-Small Cell Lung Cancer Clinical Trials
A listing of 144 Non-Small Cell Lung Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 144
Featured Trial
Non-Small Cell Lung Cancer Treatment
Recruiting
A Trial to Evaluate DZD9008 as a Treatment for People with Non-Small Cell Lung Cancer with EGFR Gene Mutations
Conditions:
NSCLC
Lung Cancer
Non-Small Cell Lung Cancer
Carcinoma
Non-Small-Cell Lung
Lung Diseases
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Resistant Hypertension Clinical Trial
Recruiting
This clinical trial is seeking volunteers that take blood pressure medications daily and still routinely have a systolic (top number) blood pressure above 145.
Conditions:
High Blood Pressure
Hypertension
Resistant Hypertension
Featured Trial
Herpes Clinical Trial
Recruiting
Help move the future of herpes simplex virus type 2 (HSV-2) genital herpes forward by participating in the Vantage Trial for an investigational vaccine.
Conditions:
HSV-2 Infection
HSV-2
Herpes
Herpes Simplex
Genital Herpes
Genital Herpes Simplex Type 2
HSV-2 Genital Herpes
HIV-1 and HSV-2 Coinfection
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Mitchell Cancer Institute; Pharmacy, Mobile, Alabama +59 locations
Conditions: Non-small Cell Lung Cancer
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Recruiting
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab or AZD0171 and platinum doublet chemotherapy; or MEDI5752 in combination with platinum doublet chemotherapy or datopotamab deruxtecan (Dato-DXd) in combination with durvalumab and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
11/30/2023
Locations: Research Site, Little Rock, Arkansas +94 locations
Conditions: Non-small Cell Lung Cancer
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
Recruiting
Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Southern Cancer Center, Daphne, Alabama +149 locations
Conditions: Non-small Cell Lung Cancer
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Recruiting
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Palo Verde Hematology Oncology Ltd, Glendale, Arizona +147 locations
Conditions: Non-small Cell Lung Cancer
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Recruiting
The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona +34 locations
Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Recruiting
Background:
A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs in a laboratory. A type of virus is used to transfer the genes that make those white blood cells able to attack the mutation in the tumor. The gene transfer therapy is the return of those white blood... Read More
Gender:
All
Ages:
Between 18 years and 72 years
Trial Updated:
11/29/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Endocrine Tumors, Neuroendocrine Tumors, Gastrointestinal/Genitourinary Cancers, Multiple Myeloma
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Recruiting
A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of therapeutic agents to improve outcomes.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/28/2023
Locations: University of Colorado, Cancer Center, Aurora, Colorado
Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors.
ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called treatment arms. The Recommended Phase 2 dose (RP2D) will be explored. Each treatment arm rece... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: University of California, Los Angeles/ID# 243841, Santa Monica, California +63 locations
Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
Recruiting
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +29 locations
Conditions: Non-small Cell Lung Cancer
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Recruiting
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab (MK-3475A) administered subcutaneously (SC) over pembrolizumab (MK-3475) administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Alaska Oncology and Hematology ( Site 0121), Anchorage, Alaska
Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Recruiting
Background:
Surgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return. Radiation and chemotherapy can improve survival in some people who have had surgery for NSCLC, but these treatments also cause serious side effects. A new approach, called immunotherapy, may be a better way to stop NSCLC tumors from coming back.
Objective:
To test a new treatment (H1299 lung cancer cell vaccine combined with the drug N-803)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Recruiting
This study will test the safety of a drug called SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.
This study will have 3 parts. Parts A and B of the study will find out how much SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if SGN-BB228 is safe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: University of California, San Francisco | HDFCCC - Hematopoietic Malignancies, San Francisco, California +10 locations
Conditions: Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
1 - 12 of 144